2024
Canonical Amplifications and CDKN2A/B Loss Refine IDH1/2-mutant Astrocytoma Prognosis
Ghosh H, Patel R, Claus E, Castro L, Wen P, Ligon K, Meredith D, Bi W. Canonical Amplifications and CDKN2A/B Loss Refine IDH1/2-mutant Astrocytoma Prognosis. Neuro-Oncology 2024, noae258. PMID: 39584448, DOI: 10.1093/neuonc/noae258.Peer-Reviewed Original ResearchFocal gene amplificationsCDKN2A/B lossFocal amplificationGene amplificationAssociated with worse survivalAssociated with reduced survivalGrade 4 casesGrade 4 patientsLoss of CDKN2A/BMolecular featuresOverall survival predictionIntermediate prognosisTumor gradeWorse survivalIDH1/2-mutantShorter survivalHistological criteriaStratify riskPoor outcomeHistological featuresCDKN2A/BHomozygous lossAcademic medical centerGrade 2Glioma diagnosticsEPID-22. MUTATIONAL SIGNATURE ASSOCIATED WITH HALOALKANE EXPOSURE ENRICHED IN FIREFIGHTERS IN THE ADULT GLIOMA STUDY
Cannataro V, Bracci P, Taylor J, McCoy L, Rice T, Hansen H, Heffernan A, Wiemels J, Wiencke J, Wrensch M, Claus E. EPID-22. MUTATIONAL SIGNATURE ASSOCIATED WITH HALOALKANE EXPOSURE ENRICHED IN FIREFIGHTERS IN THE ADULT GLIOMA STUDY. Neuro-Oncology 2024, 26: viii142-viii142. PMCID: PMC11553659, DOI: 10.1093/neuonc/noae165.0558.Peer-Reviewed Original Research
2023
EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018
Neff C, Price M, Gerstl J, Kruchko C, Barnholtz-Sloan J, Bernstock J, Smith T, Claus E, Ostrom Q. EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018. Neuro-Oncology 2023, 25: v121-v121. PMCID: PMC10639734, DOI: 10.1093/neuonc/noad179.0460.Peer-Reviewed Original ResearchCentral nervous system tumorsNervous system tumorsTotal YLLYears of lifeSystem tumorsAtypical teratoid/rhabdoid tumorCancer-specific mortalityShorter survival timeNon-malignant tumorsCDC's National ProgramNational Vital Statistics SystemRace/ethnicityAge of deathNational burdenCancer morbidityVital Statistics SystemSpecific histopathologyRhabdoid tumorSurvival timeLife LostPremature deathTumorsYLLNational programMortality dataQOL-09. QUALITY OF LIFE AFTER SURGERY FOR LOWER GRADE GLIOMAS
Heffernan A, Wu Y, Benz L, Verhaak R, Kwan B, Claus E. QOL-09. QUALITY OF LIFE AFTER SURGERY FOR LOWER GRADE GLIOMAS. Neuro-Oncology 2023, 25: v250-v250. PMCID: PMC10639580, DOI: 10.1093/neuonc/noad179.0961.Peer-Reviewed Original ResearchLow-grade gliomasGrade gliomasNon-malignant brain tumoursShort Form Health SurveyBackground Limited dataForm Health SurveyGeneral healthy populationGroup of patientsMedical Outcomes StudyCase/control studyLong-term qualityTime of interviewResidents of ConnecticutQOL outcomesSample average ageHealth SurveyOutcome studiesMeningioma casesTreatment groupsBrain tumorsAverage ageControl studyHealthy populationControl populationPrime of life
2021
A molecularly integrated grade for meningioma
Driver J, Hoffman SE, Tavakol S, Woodward E, Maury EA, Bhave V, Greenwald NF, Nassiri F, Aldape K, Zadeh G, Choudhury A, Vasudevan HN, Magill ST, Raleigh DR, Abedalthagafi M, Aizer AA, Alexander BM, Ligon KL, Reardon DA, Wen PY, Al-Mefty O, Ligon AH, Dubuc AM, Beroukhim R, Claus EB, Dunn IF, Santagata S, Bi W. A molecularly integrated grade for meningioma. Neuro-Oncology 2021, 24: 796-808. PMID: 34508644, PMCID: PMC9071299, DOI: 10.1093/neuonc/noab213.Peer-Reviewed Original ResearchConceptsMeningioma patientsWHO gradeGrading systemCommon primary intracranial tumorWorld Health Organization gradeProgression-free survivalAdditional prognostic informationPrimary intracranial tumorsCox proportional hazardsGrading schemeTime-dependent areaSurgical resectionChromosomal copy-number dataClinical behaviorHistopathology featuresPrognostic informationPatient managementIntracranial tumorsDiscovery cohortClinical careIndependent cohortMitotic countPatientsProportional hazardsMeningiomasEnvironmental and sex-specific molecular signatures of glioma causation
Claus EB, Cannataro VL, Gaffney SG, Townsend JP. Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology 2021, 24: 29-36. PMID: 33942853, PMCID: PMC8730771, DOI: 10.1093/neuonc/noab103.Peer-Reviewed Original ResearchConceptsIDH wild-type tumorsWild-type tumorsEnvironmental risk factorsIDH-mutant tumorsRisk factorsCases of gliomaMolecular signaturesPIK3CA mutationsPossible risk exposuresMutation subtypesCancer effectsExogenous exposureAdult gliomasTumorsWhole-exome sequencing dataGliomasKinase domainMutational signaturesCancer-causing mutationsMalesFemalesNon-coding regionsPIK3R1SexCancer mutational signatures
2020
Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis
Feliciano JT, Salmi L, Blotner C, Hayden A, Nduom EK, Kwan BM, Katz MS, Claus EB. Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis. Journal Of Medical Internet Research 2020, 22: e22005. PMID: 33030435, PMCID: PMC7582142, DOI: 10.2196/22005.Peer-Reviewed Original Research
2019
Longitudinal molecular trajectories of diffuse glioma in adults
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW. Longitudinal molecular trajectories of diffuse glioma in adults. Nature 2019, 576: 112-120. PMID: 31748746, PMCID: PMC6897368, DOI: 10.1038/s41586-019-1775-1.Peer-Reviewed Original ResearchConceptsAdult patientsDiffuse gliomasRecurrent gliomaOverall survivalPoor outcomeCurrent therapiesChromosome arms 1p/19qAcquired alterationsMajor subtypesTherapeutic resistanceGliomasGlioma developmentGene alterationsIDH mutationsGlioma subtypesPatientsHypermutator phenotypeDriver genesSubtypesClinical annotationSurvivalSubclonal selectionCell cycleAlterationsLittle evidenceEPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA
Poisson L, Kouwenhoven M, Snyder J, Alfaro-Munoz K, Kaur M, Bates A, Verhaak R, Watts C, Zadeh G, Ormond D, Claus E, Khasraw M. EPID-23. PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA. Neuro-Oncology 2019, 21: vi79-vi79. PMCID: PMC6847827, DOI: 10.1093/neuonc/noz175.323.Peer-Reviewed Original ResearchAdult malignant gliomasCommon data elementsMalignant gliomasGlioma researchRetrospective chart abstractionLongitudinal studySmall patient populationMulti-center collaborationResearch Electronic Data Capture (REDCap) systemChart abstractionPatient demographicsClinical courseClinical featuresOngoing trialsClinical variablesPatient populationUncommon cancerMedical historyClinical dataTranslational studiesGlioma Longitudinal Analysis ConsortiumClinical standardsMultidisciplinary expertsConfirmatory studiesGliomasLack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis
Saunders CN, Cornish AJ, Kinnersley B, Law PJ, Claus EB, Il’yasova D, Schildkraut J, Barnholtz-Sloan JS, Olson SH, Bernstein JL, Lai RK, Chanock S, Rajaraman P, Johansen C, Jenkins RB, Melin BS, Wrensch MR, Sanson M, Bondy ML, Houlston RS. Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis. Neuro-Oncology 2019, 22: 207-215. PMID: 31665421, PMCID: PMC7442418, DOI: 10.1093/neuonc/noz209.Peer-Reviewed Original ResearchConceptsDensity lipoprotein cholesterolGlioma riskLipoprotein cholesterolRisk factorsHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMultiple potential risk factorsInsulin-like growth factor-1Modifiable risk factorsSystolic blood pressureBody mass indexPotential risk factorsSerum immunoglobulin E.Body fat percentageGrowth factor-1Risk of gliomaFatty acid levelsLack of associationMendelian randomisation analysisBlood pressureTotal cholesterolWaist circumferenceHemoglobin levelsInflammatory factorsMass indexSocial media partnerships with patient organizations for neuro-oncology patient recruitment
Claus EB, Feliciano J, Benz LS, Calvocoressi L. Social media partnerships with patient organizations for neuro-oncology patient recruitment. Neuro-Oncology Practice 2019, 7: 143-151. PMID: 32626583, PMCID: PMC7318861, DOI: 10.1093/nop/npz049.Peer-Reviewed Original ResearchNeuro-oncology patientsPatient organizationsNational Cancer Institute's SurveillanceEnd Results (SEER) dataTumor RegistryPathology reportsTreatment responsePatient recruitmentEpidemiologic studiesNeuro-oncologyPatientsYale University SchoolSaliva specimenSuccessful enrollmentEnrollment methodsDisease etiologyAssociation websitesRegistryPublic healthUniversity SchoolParticipant populationResult dataSurveillanceOnline questionnaireParticipantsGlioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics
Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel‐Passow J, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz‐Sloan J, Bondy ML. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. International Journal Of Cancer 2019, 146: 739-748. PMID: 30963577, PMCID: PMC6785354, DOI: 10.1002/ijc.32318.Peer-Reviewed Original ResearchTranscriptome-wide association study identifies new candidate susceptibility genes for glioma
Atkins I, Kinnersley B, Ostrom QT, Labreche K, Il'yasova D, Armstrong GN, Eckel-Passow JE, Schoemaker MJ, Nöthen MM, Barnholtz-Sloan JS, Swerdlow AJ, Simon M, Rajaraman P, Chanock SJ, Shildkraut J, Bernstein JL, Hoffmann P, Jöckel KH, Lai RK, Claus EB, Olson SH, Johansen C, Wrensch MR, Melin B, Jenkins RB, Sanson M, Bondy ML, Houlston RS. Transcriptome-wide association study identifies new candidate susceptibility genes for glioma. Cancer Research 2019, 79: canres.2888.2018. PMID: 30709929, PMCID: PMC6522343, DOI: 10.1158/0008-5472.can-18-2888.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesTranscriptome-wide association studyNovel risk lociRisk lociAssociation studiesCausal genesGenotype-Tissue Expression project dataNew candidate susceptibility genesGlioma risk variantsGWAS-identified variantsGWAS summary statisticsGlioma risk lociBonferroni-corrected significance levelCandidate susceptibility genesGWAS lociNew genesNovel lociGene expressionGenesLociSusceptibility variantsSusceptibility genesRisk variantsGlioma tumorigenesisNon-GBM tumorsAspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis
Amirian ES, Ostrom QT, Armstrong GN, Lai RK, Gu X, Jacobs DI, Jalali A, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut JM, Ali-Osman F, Sadetzki S, Jenkins RB, Lachance DH, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Johansen C, Houlston RS, Scheurer ME, Shete S, Amos CI, Melin B, Bondy ML. Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis. Cancer Epidemiology Biomarkers & Prevention 2019, 28: cebp.0702.2018. PMID: 30482874, PMCID: PMC6401283, DOI: 10.1158/1055-9965.epi-18-0702.Peer-Reviewed Original ResearchLonger genotypically-estimated leukocyte telomere length is associated with increased meningioma risk
Muskens IS, Hansen HM, Smirnov IV, Molinaro AM, Bondy ML, Schildkraut JM, Wrensch M, Wiemels JL, Claus EB. Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk. Journal Of Neuro-Oncology 2019, 142: 479-487. PMID: 30796745, PMCID: PMC6482066, DOI: 10.1007/s11060-019-03119-w.Peer-Reviewed Original ResearchConceptsMeningioma riskBrain tumorsNon-malignant brain tumoursMalignant brain tumorsEtiology of meningiomaHealthy controlsOdds ratioMeningioma patientsMeningioma casesSurvival rateLogistic regressionMeningiomasGermline DNATelomere lengthTumorsMultiple testingRiskEuropean ancestryWestern European ancestryPatientsPathophysiologyLymphocytesConclusionIncreasedEtiologyControl
2018
Genome-wide association analysis identifies a meningioma risk locus at 11p15.5
Claus EB, Cornish AJ, Broderick P, Schildkraut JM, Dobbins SE, Holroyd A, Calvocoressi L, Lu L, Hansen HM, Smirnov I, Walsh KM, Schramm J, Hoffmann P, Nöthen MM, Jöckel KH, Swerdlow A, Larsen SB, Johansen C, Simon M, Bondy M, Wrensch M, Houlston RS, Wiemels JL. Genome-wide association analysis identifies a meningioma risk locus at 11p15.5. Neuro-Oncology 2018, 20: 1485-1493. PMID: 29762745, PMCID: PMC6176799, DOI: 10.1093/neuonc/noy077.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCase-Control StudiesChromosomes, Human, Pair 11FemaleFollow-Up StudiesGenetic LociGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansLinkage DisequilibriumMaleMeningeal NeoplasmsMeningiomaMiddle AgedPolymorphism, Single NucleotidePrognosisRisk FactorsYoung AdultConceptsGenome-wide association studiesRisk lociGenome-wide association analysisSusceptibility lociNeural crest-derived structuresSignificant heritable basisNumber of genesIndependent sample seriesNew susceptibility lociHeritable basisGenetic basisGenome ProjectAssociation studiesAssociation analysisLinkage disequilibriumLociMeningioma developmentReference panelPolygenic modelCentral roleUK10K dataAdult brain tumorsRIC8AMeningeal coveringsGenesA gene expression signature predicts recurrence-free survival in meningioma
Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget 2018, 9: 16087-16098. PMID: 29662628, PMCID: PMC5882319, DOI: 10.18632/oncotarget.24498.Peer-Reviewed Original ResearchGlioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium
Aldape K, Amin SB, Ashley DM, Barnholtz-Sloan JS, Bates AJ, Beroukhim R, Bock C, Brat DJ, Claus EB, Costello JF, de Groot JF, Finocchiaro G, French PJ, Gan HK, Griffith B, Herold-Mende CC, Horbinski C, Iavarone A, Kalkanis SN, Karabatsou K, Kim H, Kouwenhoven MCM, McDonald KL, Miletic H, Nam DH, Ng HK, Niclou SP, Noushmehr H, Ormond D, Poisson LM, Reifenberger G, Roncaroli F, K J, Smitt P, Smits M, Souza CF, Tabatabai G, Van Meir EG, Verhaak RGW, Watts C, Wesseling P, Woehrer A, Yung WKA, Jungk C, Hau AC, van Dyck E, Westerman BA, Yin J, Abiola O, Zeps N, Grimmond S, Buckland M, Khasraw M, Sulman EP, Muscat AM, Stead L. Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology 2018, 20: 873-884. PMID: 29432615, PMCID: PMC6280138, DOI: 10.1093/neuonc/noy020.Peer-Reviewed Original ResearchConceptsGlioma Longitudinal Analysis ConsortiumMolecular evolutionAnalysis ConsortiumEvolution of gliomasLethal phenotypeCancer Genome AtlasEpigenetic abnormalitiesTargetable vulnerabilitiesGenome AtlasSomatic alterationsDiverse groupCurrent knowledgeAdult diffuse gliomasComprehensive understandingDiffuse gliomasKnowledge gapsEssential insightsEvolutionMolecular subtypesConsortiumPhenotype
2017
Quality of life after surgery for intracranial meningioma
Benz LS, Wrensch MR, Schildkraut JM, Bondy ML, Warren JL, Wiemels JL, Claus EB. Quality of life after surgery for intracranial meningioma. Cancer 2017, 124: 161-166. PMID: 28902404, PMCID: PMC6415762, DOI: 10.1002/cncr.30975.Peer-Reviewed Original ResearchConceptsMedical Outcomes Study Short Form-36 Health SurveyShort Form-36 Health SurveyGeneral healthy populationCase-control studyLong-term qualityCase/control statusResidents of ConnecticutDomains of PhysicalRole PhysicalRole EmotionalInitial diagnosisQOL outcomesHealthy controlsClinical significanceHealth SurveyMeningioma casesIntracranial meningiomasCurrent studyHealthy populationControl statusTelephone interviewsPatientsMental healthMeningiomasSignificant decreaseResponse of melanoma brain metastases to ipilimumab: a retrospective review. (P5.174)
Wang N, Huang R, Lian C, Sullivan R, Buchbinder E, Claus E, Brastianos P, Bailey N, Aizer A, Rahman R, Donahue H, Davis M, Ibrahim N, Lee E. Response of melanoma brain metastases to ipilimumab: a retrospective review. (P5.174). Neurology 2017, 88 DOI: 10.1212/wnl.88.16_supplement.p5.174.Peer-Reviewed Original Research